IL17A and ductal breast carcinoma in situ: Thus, our work warrants further mechanistic investigation of IL-17 signaling and TANs to identify or therapeutically target DCIS lesions that may be capable of aggressive behavior, including the use of SX-682 in patients at risk for aggressive progression.